MedTrace Logo

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

NCT06686030 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-04-16

No results posted yet for this study

Summary

An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)

Conditions

  • Platinum-sensitive Ovarian Cancer

Interventions

DRUG

AK112 low dose

10mg/kg, Q3W, ivgtt

DRUG

Chemotherapy

ivgtt

DRUG

Olaparib

bid, oral

DRUG

AK112 high dose

20mg/kg, Q3W, ivgtt

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2027-10-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686030 on ClinicalTrials.gov